In last trading session, Calidi Biotherapeutics Inc (AMEX:CLDI) saw 0.49 million shares changing hands with its beta currently measuring 0.57. Company’s recent per share price level of $0.20 trading at $0.0 or -1.99% at ring of the bell on the day assigns it a market valuation of $7.04M. That closing price of CLDI’s stock is at a discount of -6795.0% from its 52-week high price of $13.79 and is indicating a premium of 30.0% from its 52-week low price of $0.14. Taking a look at company’s average trading volume volume of 1.02 million if we extend that period to 3-months.
Calidi Biotherapeutics Inc (AMEX:CLDI) trade information
Upright in the red during last session for losing -1.99%, in the last five days CLDI remained trading in the green while hitting it’s week-highest on Monday, 04/29/24 when the stock touched $0.20 price level, adding 37.52% to its value on the day. Calidi Biotherapeutics Inc’s shares saw a change of -86.95% in year-to-date performance and have moved 22.59% in past 5-day. Calidi Biotherapeutics Inc (AMEX:CLDI) showed a performance of -53.52% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Calidi Biotherapeutics Inc (CLDI) estimates and forecasts
Statistics highlight that Calidi Biotherapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -89.90% of value to its shares in past 6 months, showing an annual growth rate of 49.13% while that of industry is 12.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
CLDI Dividends
Calidi Biotherapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
